Latest News about Biotech
Recent news which mentions Biotech
23andMe's Anne Wojcicki now says her take-private plan is the best option for company
October 01, 2024
From Business Journals
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
September 30, 2024
From Benzinga
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
September 30, 2024
From Benzinga
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
From Benzinga
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
September 30, 2024
From Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
September 30, 2024
From Benzinga
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
September 30, 2024
From Benzinga
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
September 27, 2024
From Benzinga
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
September 27, 2024
From Benzinga
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
September 27, 2024
From Benzinga
From Benzinga
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
September 27, 2024
From Benzinga
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
September 27, 2024
From Benzinga
BioAge seeks nearly $200 million in initial public offering
September 27, 2024
From Business Journals
TBJ Fast 50 2024: No. 27 – Core Technology Molding Corp.
September 26, 2024
From Business Journals
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.